Abiopharma

🔍 Walrath Michael (Director)

Company: Yext, Inc. (YEXT)

Report Date: 2026-03-20

Detailed Transactions and Holdings:

• Acquired 78,125 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,493,242.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 312,500 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,805,742.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Acquired 54,571 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,860,313.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 211,729 shares of Common Stock at $4.79 per share (Direct)
  Date: 2026-03-20 | Code: F | equity_swap_involved: 0 | shares_owned_after: 3,648,584.00 | transaction_form_type: 4 | Footnotes: F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 32,485.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 16,265.00 | Footnotes: F6
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 16,237.00 | Footnotes: F7
• Sold 78,125 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 312,500.00 | transaction_form_type: 4 | Footnotes: F1, F8, F8
• Sold 312,500 shares of Performance-Based Restricted Stock Unit (Derivative)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 312,500.00 | transaction_form_type: 4 | Footnotes: F3, F2, F2

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Yext, Inc.'s (the "Company") common stock.
• F2: A target of 625,000 performance-based RSUs ("PSUs") become eligible to vest based upon achievement of a combination of performance as measured using a measurement in growth of the Company's reported ARR and a "Rule of 40" summation of the percentage growth in the reported ARR and Adjusted EBITDA Margins over each of fiscal 2026 and fiscal 2027 (each, a "Performance Period"). 50% of the total target PSUs will be eligible to be earned in each Performance Period, and the maximum number of PSUs that may become eligible to vest in connection with achievement in excess of the target shall be no more than 250% of the target PSUs. The PSUs that become eligible to vest with respect to a Performance Period will vest on March 20 following the end of that Performance Period, subject to reporting person's continued service through that date. For the first Performance Period, 367,071 PSUs vested on March 20, 2026 based on achievement of approximately 117.46% performance for 312,500 target PSUs.
• F3: Each PSU represents a contingent right to receive one share of the Company's common stock.
• F4: Shares withheld to satisfy tax liability upon vesting of restricted stock units on March 20, 2026.
• F5: Securities are held by a trust the beneficiaries of which are the Reporting Person's children.
• F6: Securities are held by a trust of which the Reporting Person's spouse is the trustee and the beneficiaries of which are certain family members of the Reporting Person.
• F7: Securities are held by a trust, separate from the trust referenced in footnote 6, of which the Reporting Person's spouse is the trustee and the beneficiaries of which are certain family members of the Reporting Person.
• F8: One-eighth of shares subject to the award vested on June 20, 2025 and vests quarterly thereafter on each September 20, December 20, March 20 and June 20, subject to the reporting person's continued service on each such date, until the award is fully vested on March 20, 2027.